Diagnostic systems for Lassa fever (LF), a viral hemorrhagic fever caused by Lassa virus (LASV), such as enzyme immunoassays for the detection of LASV antibodies and LASV antigens, were developed using the recombinant nucleoprotein (rNP) of LASV (LASV-rNP). The LASV-rNP was expressed in a recombinant baculovirus system. LASV-rNP was used as an antigen in the detection of LASV-antibodies and as an immunogen for the production of monoclonal antibodies. The LASV-rNP was also expressed in HeLa cells by transfection with the expression vector encoding cDNA of the LASV-NP gene. An immunoglobulin G enzymelinked immunosorbent assay (ELISA) using LASV-rNP and an indirect immunofluorescence assay using LASV-rNP-expressing HeLa cells were confirmed to have high sensitivity and specificity in the detection of LASV-antibodies. A novel monoclonal antibody to LASV-rNP, monoclonal antibody 4A5, was established. A sandwich antigen capture (Ag-capture) ELISA using the monoclonal antibody and an anti-LASV-rNP rabbit serum as capture and detection antibodies, respectively, was then developed. Authentic LASV nucleoprotein in serum samples collected from hamsters experimentally infected with LASV was detected by the Ag-capture ELISA. The Ag-capture ELISA specifically detected LASV-rNP but not the rNPs of lymphocytic choriomen ingitis virus or Junin virus. The sensitivity of the Ag-capture ELISA in detecting LASV antigens was compa rable to that of reverse transcription-PCR in detecting LASV RNA. These LASV rNP-based diagnostics were confirmed to be useful in the diagnosis of LF even in institutes without a high containment laboratory, since the antigens can be prepared without manipulation of the infectious viruses.
Lassa fever (LF) is a viral hemorrhagic fever caused by Lassa virus (LASV), an Old World arenavirus. Many cases of LF occur in western Africa in countries such as Guinea, Sierra Leone, and Nigeria (7, 23, 27, [29] [30] [31] . It is thought that LASV infects tens of thousands of humans annually and causes hun dreds to thousands of deaths (34) . Humans become infected through contact with infected excreta, tissue, or blood from the peridomestic rodent, Mastomys natalensis, the reservoir host of LASV (34) . LASV can be transmitted to other humans via mucosal or cutaneous contact or through nosocomial contam ination (27) . More than 20 imported cases of LF have been reported outside the endemic region in areas such as the United States, Canada, Europe, and Japan (1, 2, 13, 15, 18, 24, 25) . Recently, the potential for the use of hemorrhagic fever viruses, including LASV, as a biological weapon has been em phasized (5, 6) . Therefore, the development of diagnostic sys tems for LF is important even in countries free from LF out breaks to date.
Manipulation of infectious LASV is necessary for the detec tion of specific antibodies. However, a high-containment lab oratory (biosafety level 4 [BSL-4]) is required for handling infectious LASV and, therefore, the preparation of LASV antigens cannot be implemented in institutes without a BSL-4 facility. Within this framework, it is important to develop sen sitive and specific diagnostic systems for LF that eliminate the need for the manipulation of infectious LASV. In the present study, the recombinant nucleoprotein (rNP) of LASV (LASV-rNP) was expressed and evaluated for its ability to detect LASV antibodies. LASV-rNP-based enzyme-linked immu nosorbent and indirect immunofluorescence assays (ELISA and UFA) were developed. Furthermore, novel monoclonal antibodies to LASV-rNP were generated and used in combi nation with the recombinant antigen to develop an LASV antigen (nucleoprotein) capture ELISA. The present study presents an alternative strategy to develop diagnostic systems without handling infectious LASV.
MATERIALS AND METHODS

Cells.
A HeLa cell line was cultured in the Eagle minimum essential medium supplemented with 10% fetal bovine serum and the antibiotics penicillin G and streptomycin (MEM-10FBS). Tn5 insect cells were used for the expression of the rNPs of arenaviruses (LASV, lymphocytic choriomeningitis virus [LCMVJ, and Junin virus [JUNV]) in a baculovirus system. The Tn5 insect cells were cultured as reported previously (38) . (28) . Clones containing the insert in the correct orientation were selected, and the plasmid DNA was used for cotransfection in Sf21 cells with a polyhedrin-positive AcMNPV DNA, and the supernatant culture was screened for a polyhedrin-negative phenotype by plaque assay (19) . Finally, recombinant baculovirus clones overexpressing JUNV-rNP were obtained after three succes sive plaque purifications. One of them, designated AcNMPV-Jun-N'122, was used in the present study and is referred to hereafter as Ac-JUNV-NP.
Expression and purification of His-LASV-rNP, LCMV-rNP, and JUNV-rNP.
Tn5 cells infected with Ac-His-LASV-NP were incubated at 26°C for 72 h. The cells were then washed twice with cold phosphate-buffered saline (PBS) solution. A preliminary study demonstrated that most of the Tn5 cellular proteins were solubilized in PBS containing 2 M urea (PBS-2 M urea) but that the His-LASV-rNP was insoluble and that the LASV-rNP could be solubilized in PBS contain ing 8 M urea (PBS-8 M urea). Therefore, the Tn5 cells infected with Ac-His-LASV-NP were first suspended in PBS-2 M urea. After the centrifugation of the cell suspensions at 15,000 X g for 10 min, the pellet fractions were collected and then were solubilized in PBS-8 M urea. After the centrifugation of the samples, the supernatant fractions were used as the purified antigens. LCMV-rNP and JUNV-rNP showed dissolution characteristics in urea similar to those of His-LASV-rNP; therefore, LCMV-rNP and JUNV-rNP were also fractioned in the same way as the His-LASV-rNP. The control antigen was produced from Tn5 cells infected with Ac-AP in the same manner as that for the positive antigens. The His-LASV-rNP was also purified by using the Ni2+ column purification method as reported previously (38) . The source for His-LASV-rNP-purification was the supernatant fraction of the PBS-8 M urea-treated Tn5 cells infected with Ac-His-LASV-NP after sufficient dilution with PBS in order to reduce the urea concentration.
SDS-PAGE. The expression and purification efficiency of His-LASV-rNP, LCMV-rNP, and JUNV-rNP were analyzed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels (12% polyacrylamide) after staining with Coomassie blue.
Establishment of MAbs. Monoclonal antibodies (MAbs) were generated as previously described (32, 41) . BALB/c mice were immunized with purified His-LASV-rNP in the present study. Isotypes of the MAbs were determined by using a mouse MAb isotyping kit (Life Technologies).
Expression of truncated NPs of LASV. In order to determine the epitope of the MAbs to the His-LASV-rNP, truncated LASV-rNPs were expressed as a form of fusion protein with glutathione S-transferase (GST) as shown in Fig. 1 . The DNA corresponding to each of the truncated NP fragments was amplified with the designed primers. The amplified DNA was subcloned into the BamHI and EcoRI cloning sites of plasmid pGEX-2T (Amersham Pharmacia Biotech, Buckinghamshire, England). Each insert was sequenced and confirmed to be in the correct frame and identical to the original sequence. The GST-tagged nu cleoprotein fragments were expressed in an Escherichia coli BL21 system.
Western blotting. The MAbs were tested for reactivity to His-LASV-rNP and its fragments by Western blotting as reported previously (17, 32, 41) .
Pepscan analyses. ELISA was performed as reported previously with the purified rNP or partial nucleoprotein peptides as the antigen (33) . The peptides 1184 SAIJO ET AL.
Clin. Vaccine Immunol. were shifted by 1 amino acid (aa), with a consecutive overlap of 9 aa to cover the entire LASV-NP1 (aa 1 to 100) and LASV-NP5 (aa 361 to 460) fragments. Linear epitopes on the NP were determined by using Pepscan (Chiron Technol ogies, Clayton, Australia) according to the manufacturer's instructions. Ninetysix peptides were prepared as 14-aa biotinylated peptides, including a 4-aa spacer sequence (SGSG) at the amino-terminal end, according to each of the amino acid sequences of the LASV-rNPl and LASV-rNP5 of the LASV Josiah strain. The methods were previously described in detail (33) .
IgG-ELISA. Immunoglobulin G (IgG)-ELISA was performed as previously described except for the antigen preparation (38, 39) . Briefly, ELISA plates (96-well type plate, Pro-Bind; Falcon; Becton Dickinson Labware, Franklin Lakes, NJ) were coated with the predetermined optimal quantity of purified His-LASV-rNP, LCMV-rNP, or JUNV-rNP (approximately 100 n^well) at 4°C overnight. Then, each well of the plates was inoculated with 200 |xl of PBS containing 5% skim milk and 0.05% Tween 20 (M-T-PBS), followed by incuba tion for 1 h for blocking. The plates were washed three times with T-PBS and then inoculated with the test samples (100 pl/well), which were diluted fourfold from 1:100 to 1:6,400 with M-T-PBS. After a 1-h incubation period, the plates were washed three times with T-PBS, and then the plates were inoculated with goat anti-human IgG antibody labeled with HRPO (1:1,000 dilution; Zymed Laboratory). After a further 1-h incubation period, the plates were washed and 100 pd of ABTS [2,2'azinobis(3-ethylbenzthiazolinesulfonic acid)] solution (Roche Diagnostics, Mannheim, Germany) was added to each well. The plates were incubated for 30 min at room temperature, and optical density was at 405 nm (OD405) was measured against a reference of 490 nm. The adjusted OD405 was calculated by subtracting the OD of the negative antigen-coated wells from that of the corresponding wells. The means and standard deviations were calcu lated from the 96 control sera. The cutoff value for the assay was defined as the mean plus 3 standard deviations.
Immunofluorescence. The pQE32-LASV-NP was digested with BamHI, and the insert was subcloned into the BamHI site of the pKS336 vector (40) . The LASV-NP gene that was inserted into the pKS336 vector, pKS336-LASV-NP, was confirmed to be in the correct orientation to the promoter, tested for nucleotide sequencing as described above, and the nucleotide sequence of the gene was confirmed to be identical to the original sequence. HeLa cells were then transfected with pKS336-LASV-NP by using a FuGENE6 transfection re agent (Roche Diagnostics) according to the manufacturer's instructions. The cells transfected with the plasmid were selected with 3 pg of blasticidin Shydrochloride/ml in MEM-10FBS. The HeLa cell clones were analyzed for the expression of LASV-rNP by UFA using the rabbit serum raised against His-LASV-rNP. The cells expressing LASV-rNP were subcloned and used as UFA antigens.
Ag-capture ELISA. Ag-capture ELISA was performed as previously described (32, 41) . The purified MAb to His-LASV-rNP, MAb 4A5, produced in the present study was diluted in PBS solution, and 100 pl was adsorbed overnight at 4°C onto the immunoplates (96-well type plate, Pro-Bind, Falcon; Becton Dick inson Labware). Purified MAb 4A5 was coated onto the immunoplates at a concentration of approximately 100 ng/well in 100 pl of PBS. The difference in the procedures between the Ag-capture ELISA in the present study and those in previous studies (32, 37, 41) is that the MAb, MAb 4A5, and rabbit serum raised to His-LASV-rNP were used as capture and detector antibodies, respectively. The procedure for the Ag-capture ELISA was performed as follows. The ELISA plate was coated with capture MAb, followed by blocking of the plate with M-T-PBS, addition of the samples to the ELISA plate, detection of the captured LASV-NP with rabbit serum raised to His-LASV-rNP, detection of rabbit IgG antibody that reacted with the captured antigen with goat anti-rabbit IgG anti bodies conjugated with HRPO (Zymed Laboratories), and substrate reaction. In each run of the Ag-capture ELISA, the negative control antigen (M-T-PBS) was also tested. Serially diluted samples were added to the MAb-coated wells. The OD405 values of each well were adjusted by subtracting the OD405 value of the negative control antigen from the corresponding well. The adjusted OD405 was taken as a measure of the amount of antigen specifically bound. All samples were treated with 1% Nonidet-P40 (NP-40) in PBS to destroy the LASV virion and expose the nucleoprotein in the LASV virion.
RT-PCR. RT-PCR was performed as previously described (10) . The primers used in the RT-PCR were 36E2 (5'-ACCGGGGATCCTAGGCATT-3') and 80F2 (5'-ATATAATGATGACTGTTGTTCTTTGTGCA-3'). The RT-PCR was carried out with a Ready-to-Go RT-PCR tube (Pharmacia). The amplified PCR products were visualized with ethidium bromide in 2% agarose gel after electrophoresis. 
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treatment, whereas the rNPs of these viruses remained insol uble. After centrifugation at 15,000 x g for 10 min, pellet fractions were collected. The rNPs, which were still present in the pellet fractions, were completely solubilized in PBS-8 M urea. The samples were then centrifuged at 15,000 x g for 10 min, and the supernatant fractions of the PBS-8 M urea were confirmed to contain highly purified recombinant rNPs of arenaviruses (Fig. 2) .
Development of indirect immunofluorescence. The LASV-rNP was expressed in HeLa cells by transfection with the ex pression vector, pKS336-LASV-NP. The transfected cells were stained by anti-His-LASV-rNP rabbit serum and human serum samples from LF patients (Fig. 3 ). All 4 serum samples col lected from two LF patients showed a positive staining, but 96 control serum samples did not. The LASV-rNP-based UFA was also evaluated using serum samples collected from mon keys experimentally infected with LASV. All of the sera col lected from five LASV-infected monkeys showed a positive staining, but those from four mock-infected monkeys did not. Development of His-LASV-rNP-based IgG-ELISA. Four se rum samples collected from LF patients were determined to be positive by His-LASV-rNP-based IgG-ELISA, whereas 94 of the 96 control serum samples were determined to be negative. Thus, the sensitivity and specificity of the ELISA were 100 and 96%, respectively. All serum samples collected from five LASV-infected monkeys were determined to be positive, whereas those from four mock-infected monkeys were nega tive.
In order to examine cross-reactivity among arenaviruses in the LASV-rNP-based IgG-ELISA, antisera against LASV-rNP, LCMV-rNP, or JUNV-rNP were examined (Fig. 4) . The anti-LASV-rNP serum showed a strongly positive reaction, and anti-LCMV rNP and anti-JUNV-rNP sera showed strongly positive reactions in the IgG ELISA using the respective anti gens (Fig. 4A, B, and C) . Anti-LCMV-rNP and anti-JUNV-rNP sera showed a less strongly positive reaction in the His-LASV-rNP-based IgG-ELISA than anti-LASV-rNP serum (Fig. 4A ). Anti-LASV-rNP and anti-JUNV-rNP also showed a less strongly positive reaction in the His-LCMV-rNP-based IgG-ELISA than anti-LCMV-rNP serum (Fig. 4B ). However, anti-LASV-rNP and anti-LCMV-rNP sera showed a negative reaction in the JUNV-rNP-based IgG-ELISA (Fig. 4C ). Hu man sera from LF patients showed a highly positive reaction in the LASV-rNP-based IgG-ELISA, but sera from patients with Argentine hemorrhagic fever (AHF), which is caused by JUNV, did not (Fig. 4D) . Serum from an AHF patient showed a highly positive reaction in the JUNV-rNP-based IgG-ELISA (Fig. 4E) . These results suggest that cross-reactive antibody among arenaviruses may be detected by the newly developed LASV-rNP-based IgG-ELISA. Development of LASV Ag-capture ELISA. Three clones of a hybridoma that excreted an MAb to His-LASV-rNP were es-1186 SAIJO ET AL.
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Clin. Vaccine Immunol. tablished. The isotype of the three MAbs were identified as IgGl. These MAbs were designated MAb 4A5, MAb 6C11, and MAb 2-11. Of these MAbs, MAb 4A5 was the most effi cient in capturing His-LASV-rNP in the Ag-capture ELISA format. The Ag-capture ELISA with MAb 4A5 detected His-LASV-rNP concentrations as low as 800 pg/ml (data not shown). Furthermore, the Ag-capture ELISA detected the MOPV-NP but not the rNPs of LCMV and JUNV (data not shown).
All of the sera collected from five LASV-infected hamsters on days 11 and 16 postinfection were antigen positive in the Ag-capture ELISA using MAb 4A5 as a capture antibody, whereas the sera collected on days 0 and 4 were antigen neg ative. The OD405 values in the ELISA were highest on day 11. The reactivity patterns in each hamster in the ELISA were similar to the viremia levels (Fig. 5 ). The sera collected on days 11 and 16 were found to be LASV genome positive by RT-PCR (10) . Thus, the sensitivity of the Ag-capture ELISA was similar to that of the RT-PCR.
Determination of the epitope recognized by the monoclonal antibodies. The epitope recognized by MAbs was determined. MAb-4A5 reacted in Western blots with GST-LASV-rNPl-6 (full-length LASV-rNP), GST-LASV-rNPl-5, and GST-LASV-rNPl-4 but not with the other truncated LASV-rNPs shown in Table 1 , suggesting that MAb 4A5 reacted with a conformational epitope located on the amino-terminal portion of LASV-rNP. The epitope was maintained when the extreme amino-terminal portion, LASV-rNPl, was present but was lost when LASV-rNPl was removed. These results suggest that the extreme amino-terminal portion, LASV-rNPl, is essential for the maintenance of the conformational epitope. MAbs 6C11 and 2-11 reacted in Western blots with GST-LASV-rNPl and GST-LASV-rNP5, respectively ( Table 1 ).
The Pepscan analyses indicated that MAbs 6C11 and 2-11 recognized linear epitopes. MAbs 6C-11 and 2-11 recognized GLDFSEV (aa 41 to 47) within LASV-rNPl and FATQP (aa 439 to 443) within LASV-rNP5, respectively (Fig. 6 ). The re activity patterns of these MAbs with NPs of LASV, MOPV, LCMV, and JUNV are summarized in Table 2 .
DISCUSSION
We report here the development of diagnostic systems (an tibody and antigen detection systems) for LF using LASV-rNP.
The LASV-rNP-based IgG-ELISA was sensitive and specific in detecting anti-LASV-IgG. Although the data were not shown, an IgM-capture ELISA using purified LASV-rNP as an anti gen was developed in the same way as that shown in previous reports and detected LASV-IgM antibody (42, 43) . All sera collected from LF patients and monkeys infected with LASV showed positive reactions in the LASV-rNP-based UFA. The staining patterns of the rNP with these sera were granular in the UFA (Fig. 3) , making it easy to distinguish positives from negatives. UFA using LASV-rNP-expressing HeLa cells was also highly sensitive and specific in detecting LAS V-IgG. In the preliminary study, ca. 15% of the sera collected from 334 Ghanaians and only less than 1% of 280 Zambians showed positive reactions in the LASV-rNP-based IgG ELISA (our data). The results are considered to be compatible with the fact that LF is endemic to the western African region, including Ghana, but not to the eastern African region. The LASV-rNPbased antibody detection systems such as ELISA and UFA were suggested to be useful not only in the diagnosis of but also in the seroepidemiological study of LF.
The LASV-rNPs were expressed by a transformation system in E. coli or by recombinant baculovirus systems and have already been applied as antigens in ELISA, Western blotting, and UFA for the detection of antibodies to LASV (4, 14, 16, 22, 23, 44) . In the present study, an Ag-capture ELISA using (A) (B) 6 . Pepscan analyses to determine the epitopes of MAb 6C11 (A) and MAb 2-11 (B) . The vertical bar indicates the amino acid residues with an amino acid position within the LASV-NP. MAb 6C11 was confirmed to react with 7 aa residues positioned from aa 42 to 48 (GLDFSEV) within LASV-NP1. MoAb-2-11 was confirmed to react with 5 aa residues positioned from aa 439 to 443 (FATQP) within LASV-NP5. (C) The corresponding amino acid residues to the epitope of the MAb 6C11 and MAb 2-11 among MOPV, LCMV, and JUNV are shown. The GenBank accession numbers for the S genes of LASV, MOPV, LCMV, and JUNV are NC_004296, AY772170, AY847350, and DQ272266, respectively. The epitope of the MAb 6C11 is present not only in the nucleoprotein of LASV but also in those of MOPV and LCMV-but not in that of JUNV. 1188 SAIJO ET AL.
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MAbs to LASV-rNP was also developed. Furthermore, detec tion of the cross-reactive antibody by LASV-rNP-based IgG-ELISA was examined. The results for cross-reactivity indicate that the LASV-rNP-based IgG-ELISA detects not only anti bodies to LASV but also those to LCMV. The Ag-capture ELISA using MAb 4A5 was confirmed to be useful in the detection of authentic LASV antigen in sera serially collected from hamsters infected with LASV. The sen sitivity of the MAb 4A5-based Ag-ELISA was similar to that of conventional RT-PCR, the efficiency of which in the diagnosis of LF was previously reported (10) . Therefore, the MAb 4A5based Ag-capture ELISA is regarded as useful in the diagnosis of LF. Unfortunately, the efficacy of the MAb 4A5-based Agcapture ELISA in the diagnosis of LF was not evaluated using serum samples from patients. Thus, further study is still re quired. The three MAbs, including MAb 4A5, were character ized, and the corresponding amino acid residues within the nucleoproteins of LASV, MOPV, LCMV, and JUNV to the epitopes of MAb 6C11 and MAb 2-11 are summarized in Fig.  6C . It was of interest that LASV, MOPV, LCMV, and JUNV might be identified by analyses of the reactivity patterns of MAbs 4A5, 6C11, and 2-11 to the nucleoproteins of each virus. The nucleoproteins of all LASV strains circulating in the west ern and central parts of Africa would be detected by the MAb 4A5-based Ag-capture ELISA, since this ELISA was able to detect MOPV-NP that was different from LASV in terms of genetic and evolutional characteristics.
We have thus far reported the development of antibody and antigen detection systems using the recombinant nucleopro teins of the viruses for Ebola hemorrhagic fever, Marburg hemorrhagic fever, and Crimean-Congo hemorrhagic fever (32, 33, (36) (37) (38) (39) (40) (41) (42) . Recently, a number of highly pathogenic emerging virus infections in humans appeared, such as Nipah virus encephalitis (8) , SARS-coronavirus infections (21, 35) , and highly pathogenic avian influenza virus infections (9, 45, 46) . The strategy shown here might be applicable to the de velopment of diagnostic systems for severe viral infections whose etiologic agents are highly pathogenic to humans as an alternative method to methods using infectious viruses.
